💊Mitsubishi Tanabe Pharma Corporation] Notice regarding acquisition of manufacturing and sales approval for Rupafin tablets Allergy treatment agent with new mechanism of action shows strong effectiveness with dual action (anti-PAF and antihistamine action) 20170927 💊Mitsubishi Tanabe Pha Thursday September 28th, 2017By Tokio X'press JPN, Pharmaceutical mt-pharma 💊Mitsubishi Tanabe Pha
👾Japan Ministry of Health, Labor and Welfare Approves Opdivo (nivolumab) for the Treatment of Patients with Unresectable Advanced or Recurrent Gastric Cancer Which Has Progressed After Chemotherapy 👾Japan Ministry of Hea Saturday September 23rd, 2017By Tokio X'press JPN, Pharmaceutical, USA Bristol-Myers Squibb 👾Japan Ministry of Hea
🎗CELLULAR DYNAMICS INTERNATIONAL SIGNS AGREEMENT WITH NANION TECHNOLOGIES TO ENHANCE MUTUAL OFFERINGS FOR RESEARCHERS . 🎗CELLULAR DYNAMICS INT Thursday September 21st, 2017By Tokio X'press JPN, Pharmaceutical Fujifilm USA 🎗CELLULAR DYNAMICS INT
👾Opdivo® (Nivolumab) Intravenous Infusion Approved for Expanded Use in Advanced Non-squamous Non-small Cell Lung Cancer which Has Been Previously Treated with Platinum-based Therapy in Taiwan News Release 👾Opdivo® (Nivolumab) I Thursday September 21st, 2017By Tokio X'press JPN, TAI, Pharmaceutical ONO 👾Opdivo® (Nivolumab) I
Opdivo® (Nivolumab) Intravenous Infusion Approved for Expanded Use in Unresectable or Metastatic Melanoma in South Korea 20170919 Opdivo® (Nivolumab) Intravenou Tuesday September 19th, 2017By Tokio X'press JPN, Pharmaceutical ONO Opdivo® (Nivolumab) Intravenou
